Search hospitals > California > San Diego

Therapeutics Clinical Research

Claim this profile
San Diego, California 92123
Global Leader in Psoriasis
Global Leader in Atopic Dermatitis
Conducts research for Plaque Psoriasis
Conducts research for Actinic Keratosis
Conducts research for Acne
98 reported clinical trials
1 medical researcher
Photo of Therapeutics Clinical Research in San DiegoPhoto of Therapeutics Clinical Research in San DiegoPhoto of Therapeutics Clinical Research in San Diego

Summary

Therapeutics Clinical Research is a medical facility located in San Diego, California. This center is recognized for care of Psoriasis, Atopic Dermatitis, Plaque Psoriasis, Actinic Keratosis, Acne and other specialties. Therapeutics Clinical Research is involved with conducting 98 clinical trials across 63 conditions. There are 1 research doctors associated with this hospital, such as Neal D Bhatia.

Top PIs

Clinical Trials running at Therapeutics Clinical Research

Psoriasis
Plaque Psoriasis
Chronic Urticaria
Cutaneous T-Cell Lymphoma
Mycosis Fungoides
Atopic Dermatitis
Mycosis Fungoides/Sezary Syndrome
Periprosthetic Bone Loss
Male Pattern Baldness
Eczema
Image of trial facility.

ESK-001

for Plaque Psoriasis

The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to answer are: * How safe is taking ESK-001 long-term in people with moderate to severe plaque psoriasis? * Does taking ESK-001 long-term reduce the severity of people's plaque psoriasis? Patients will enter the long-term extension study following completion of one of the parent studies (ESK-001-016 or ESK-001-017) and will receive open-label ESK-001 twice daily for 24 weeks. After 24 weeks, the first 200 patients meeting at least PASI-75 clinical response will be randomly assigned to receive ESK-001 or placebo. At any point during this time, the patients losing the initial clinical response may return to the open-label ESK-001 treatment. Patients who complete Week 48 will return to open-label ESK-001 treatment and they will receive ESK-001 until the end of the study or discontinuation. All the remaining patients not meeting the entry criteria for the randomized withdrawal phase will continue to receive open-label ESK-001 for the remainder of the study. Patients taking part in the study must be men or women aged at least 18 years old and have completed a previous (parent) study of ESK-001 in moderate to severe plaque psoriasis. Patients must consent and agree to: * ensure drug daily compliance until end of study or discontinuation. * visit the clinic for checkups and assessments. * provide blood and urine samples.
Recruiting1 award Phase 31 criteria
Image of trial facility.

Hypericin

for Psoriasis

To evaluate SGX302 (topical hypericin ointment and gel) with visible light in an initial 18-week treatment course for improving lesions in patients with mild-to-moderate psoriasis.
Recruiting0 awards Phase 23 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Therapeutics Clinical Research?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security